ESLA Logo

Estrella Immunopharma Inc (ESLA) Stock Forecast & Price Prediction

Live ESLA Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$1.12

-0.03 (-2.61%)

12 Month Price Forecast For ESLA

$1.12
Current Price
$40.52M
Market Cap
0 Ratings
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to ESLA Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

ESLA Price Momentum

+6.7%
1 Week Change
+0.9%
1 Month Change
-2.6%
1 Year Change
-6.7%
Year-to-Date Change
-65.3%
From 52W High of $3.23
+77.8%
From 52W Low of $0.63

๐Ÿค” Considering Estrella Immunopharma (ESLA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 10:57 AM UTC

ESLA Analyst Ratings & Price Targets

Currently, there are no Wall Street analyst price targets or forecasts available for ESLA (Estrella Immunopharma).

ESLA is currently trading at $1.12. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ESLA Analyst Consensus

0
Buy
0
Hold
0
Sell

ESLA Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $1.12

Latest ESLA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ESLA.

Date Firm Analyst Rating Change Price Target

Stocks Similar to Estrella Immunopharma Inc

The following stocks are similar to Estrella Immunopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Estrella Immunopharma Inc (ESLA) Financial Data

Estrella Immunopharma Inc has a market capitalization of $40.52M with a P/E ratio of -4.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -171.1%.

Valuation Metrics

Market Cap $40.52M
Enterprise Value $28.05M
P/E Ratio -4.1x
PEG Ratio 0.3x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +10.3%
Current Ratio 24.6x
Debt/Equity 0.1x
ROE -171.1%
ROA -122.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Estrella Immunopharma Inc logo

Estrella Immunopharma Inc (ESLA) Company Overview

About Estrella Immunopharma Inc

What They Do

Develops T-cell therapies for cancers.

Business Model

Estrella Immunopharma focuses on developing innovative T-cell therapies targeting blood cancers and solid tumors. The company generates revenue through collaborations, clinical trials, and potential future product sales based on its promising pipeline of therapeutic candidates.

Additional Information

Founded in 2006 and headquartered in Emeryville, California, the company is currently advancing its lead product candidates through clinical and pre-clinical trials. It has established a partnership with Imugene Limited to enhance the development of treatments for solid tumors.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Dr. Cheng Liu Ph.D.

Country

United States

IPO Year

2021

Estrella Immunopharma Inc (ESLA) Latest News & Analysis

ESLA stock latest news image
Quick Summary

Estrella Immunopharma announced that the first patient in its STARLIGHT-1 Phase I/II trial achieved a complete response after receiving EB103 CD19-Redirected ARTEMISยฎ T Cells.

Why It Matters

The successful enrollment and complete response in Estrella's clinical trial can boost investor confidence, potentially leading to increased stock value and interest in the company's therapies.

Source: Business Wire
Market Sentiment: Neutral
ESLA stock latest news image
Quick Summary

Estrella Immunopharma appointed Hong Zhang as Chairperson and Board member. This follows the first patient dosing in its Phase I/II clinical trial for CD19 and CD22-targeted therapies.

Why It Matters

The appointment of a new Chairperson and progress in clinical trials can signal strategic shifts and potential advancements in product development, influencing investor sentiment and stock performance.

Source: Business Wire
Market Sentiment: Neutral
ESLA stock latest news image
Quick Summary

The IMF states most effects of tighter monetary policies on the U.S. economy have occurred, with remaining impacts expected this year. The U.S. has demonstrated resilience and growth since March 2022.

Why It Matters

The IMF's assessment indicates potential stability in the U.S. economy, suggesting less risk of recession and encouraging investor confidence amid tighter monetary policies.

Source: InvestorPlace
Market Sentiment: Positive

Frequently Asked Questions About ESLA Stock

What is Estrella Immunopharma Inc's (ESLA) stock forecast for 2025?

Analyst forecasts for Estrella Immunopharma Inc (ESLA) are not currently available. The stock is trading at $1.12.

Is ESLA stock a good investment in 2025?

Analyst ratings for ESLA are not currently available. The stock is currently trading at $1.12. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ESLA stock?

Price predictions from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.

What is Estrella Immunopharma Inc's business model?

Estrella Immunopharma focuses on developing innovative T-cell therapies targeting blood cancers and solid tumors. The company generates revenue through collaborations, clinical trials, and potential future product sales based on its promising pipeline of therapeutic candidates.

What is the highest forecasted price for ESLA Estrella Immunopharma Inc?

Price targets from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.

What is the lowest forecasted price for ESLA Estrella Immunopharma Inc?

Price targets from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.

What is the overall ESLA consensus from analysts for Estrella Immunopharma Inc?

Analyst ratings for ESLA are not currently available. The stock is trading at $1.12.

How accurate are ESLA stock price projections?

Stock price projections, including those for Estrella Immunopharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.